NCT02081755 2026-01-27
Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
Baylor Research Institute
Phase 4 Enrolling by invitation
Clinical Trials
14 trialsNCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
NCT06994572 2025-05-29
Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma
Captor Therapeutics S.A.
Phase 1 Not yet recruiting
NCT04803318 2024-06-25
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT01005199 2019-05-15
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT01379521 2017-05-03
TRACER
Novartis
Phase 2 Terminated
NCT00516165 2017-02-07
RAD001 in Advanced Hepatocellular Carcinoma
Massachusetts General Hospital
Phase 1/2 Completed
NCT01035229 2016-09-22
EVOLVE-1
Novartis
Phase 3 Completed
NCT01488487 2016-04-07
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01009801 2015-07-07
Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
Swiss Cancer Institute
Phase 1/2 Terminated
NCT00828594 2013-04-11
Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 1 Terminated
NCT00775073 2012-04-30
Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001
Treiber, Gerhard
Phase 2 Completed
NCT00390195 2009-07-02
Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 1/2 Unknown